Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilvadipine trial in mild to moderate Alzheimer's disease
ISRCTN14485052Phase 3Completed
- Sponsor
- St James's Hospital
- Start
- Apr 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Nilvadipine with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale at 78 weeks. Started Apr 2013; status: completed.
02
Drugs
nilvadipine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ISRCTN14485052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14485052.